Respiratory Season Virus Vaccines
JAMA 10.1001/jama.2026.18338September 02, 2026 at 10:00 AM EDT
This Perspective describes the Vaccine Integrity Project, established in 2025 in response to concerns about the stability and integrity of US vaccine policy due to disruptions to the work of the Advisory Committee on Immunization Practices; outlines the process for the 2026-2027 evidence review; and summarizes key findings regarding vaccine effectiveness and safety.
MEDIA ADVISORY: 2026-27 Respiratory Virus Immunization Recommendations
Recommendations are informed by JAMA evidence reviews on influenza, COVID-19, and RSV.
An accompanying Perspective describes the background of the Vaccine Integrity Project, outlines the process for the 2026-2027 evidence review, and summarizes key findings regarding vaccine effectiveness and safety.
EMBARGOED PRESS BRIEFING: Tuesday, September 1
The Vaccine Integrity Project, the American Medical Association (AMA), and leading medical specialty societies will participate in an embargoed press briefing to outline the latest data on influenza, COVID-19 and RSV immunization, and to provide evidence-based recommendations for the upcoming 2026-27 respiratory virus season.
WHAT: Embargoed press briefing for 2026-2027 respiratory virus scientific evidence and immunization recommendations
WHEN: 1 PM ET Tuesday, September 1
WHERE: The briefing will be via Zoom. Register online.
WHO:
Nicole Basta, PhD, MPhil, Vaccine Integrity Project Evidence Review Co-Lead
Christina Davidson, MD, American College of Obstetricians and Gynecologists (ACOG) Chief Medical Officer
Sandra Adamson Fryhofer, MD, AMA President-elect
Bruce Gelin, PhD, Vaccine Integrity Project Board of Advisors
Ronald G. Nahass, MD, MHCM, FIDSA, President of Infectious Diseases Society of America (IDSA)
Sarah C. Nosal, MD, FAAFP, American Academy of Family Physicians (AAFP) President
Andrew D. Racine, MD, PhD, American Academy of Pediatrics (AAP) President.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.